



1/39

FIGURE 1A




2/39

FIGURE 1B



3/39

FIGURE 1C




SUBSTITUTE SHEET (RULE 26)


4/39

FIGURE 2A

Size: 0.6360 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN



SUBSTITUTE SHEET (RULE 26)




SUBSTITUTE SHEET (RULE 26)

[illegible]

FIGURE 2C


Size: 1.4230 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN



SUBSTITUTE SHEET (RULE 26)

Size: 1.0400 mg
Method: 10 DEG C/MIN AMB TO 300
Comment: SEALED PAN


FIGURE 2D



Universal V2 5I

8/39


FIGURE 3A



SUBSTITUTE SHEET (RULE 26)


9/39

FIGURE 3B




10/39

FIGURE 3C



SUBSTITUTE SHEET (RULE 26)


11/39



SUBSTITUTE SHEET (RULE 26)

12/39

FIGURE 4



13/39

FIGURE 5





FIGURE 6A

Size: 3.3010 mg
Method: 10 deg ramp to 300 deg


methyl ethyl ketone solvent



SUBSTITUTE SHEET (RULE 26)

15/39


FIGURE 7



SUBSTITUTE SHEET (RULE 26)


16/39

FIGURE 8




SUBSTITUTE SHEET (RULE 26)

17/39




SUBSTITUTE SHEET (RULE 26)

18/39




19/39




SUBSTITUTE SHEET (RULE 26)


20/39



SUBSTITUTE SHEET (RULE 26)




22/39



SUBSTITUTE SHEET (RULE 26)


23/39

FIGURE 15




24/39

FIGURE 16




25/39

FIGURE 17



26/39

FIGURE 18




SUBSTITUTE SHEET (RULE 26)

27/39

FIGURE 19


Form

A: Cooling Rate
B: Purity
C: End Point



28/39

FIGURE 20



29/39

INEL

2 Theta





FIGURE 21

[illegible]

FIGURE 22




SUBSTITUTE SHEET (RULE 26)

31/39

FIGURE 23

Eplerenone: Dose-Ranging Heart Failure Study



[illegible]

FIGURE 24

Baseline Characteristics								
Variable Mean (SD)	Placebo n=55	EPLERENONE						p-value
		EPL 25 QD n=63	EPL 25 QD n=52	BID	EPL 50 QD n=55	EPL 100 QD n=50	SPIRO 25 QD n=46	
Age	60	62	61	62	61	62	62	0.9
M/I (%)	80/20	76/24	81/19	80/20	78/22	72/28		0.9
NYI IA II III (%)	100	97	94	100	98	100		32/39
NYI IA IV (%)	0	3	6	0	2	0		
II (%)	29	29	29	30	30	30		
IIR (BPM)	74	76	76	73	76	76		0.8
SBP (mm Hg)	127	124	128	125	129	130		0.4
DBP (mm Hg)	78	78	79	78	78	78		1.0
K ⁺ (mmol/L)	4.48	4.38	4.28	4.34	4.38	4.45		0.2
Creatinine (pmol/L)	107	109	104	107	109	107		0.7

33/39

FIGURE 25

Concurrent Medications


Category	% Patients	Avg. Dose (mg/day)
• ACE Inhibitor		
Captopril	30	62
Enalapril	30	15
Lisinopril	15	15
• Loop Diuretic		
Furosemide	85	50
• Other		
Digitalis	55	
beta-Blockers	35	
Aspirin	35	
Anticoagulants	35	
Potassium Supplements	25	
Calcium Antagonist	25	

34/39

FIGURE 26

DBP
P vs. E 50 mg/day vs. S
Mean Change (\pm SEM) at Week 12

> 90 mmHg at Baseline




35/39

FIGURE 27

Aldosterone Excretion Rate

Mean Change (+/- SEM) from Baseline at Week 12



36/39

FIGURE 28





FIGURE 29

BNP

Mean Change (+/- SEM) from Baseline at Week 12



Placebo E 25 QD E 25 BID E 50 QD E 100 QD SPIRO


p-value (vs. Placebo)

0.028 0.056 0.125 0.036 0.059

002000 2004.06.06

FIGURE 30

BNP
Mean Change (\pm SEM) from Baseline at Week 12
> 14.2 pmol/L at Baseline



Placebo	E 25 QD	E 25 BID	E 50 QD	E 100 QD	SPIRO
0.040	0.102	0.051	0.054	0.064	
p-value (vs. Placebo)					

39/39

FIGURE 31

Study Schematic For Biological Evaluation II: Multicenter, Randomized
Double-Blind, Parallel Group Trial
Minimum Trial Duration 1.012 Deaths

